Bruker, Genome BC Proteomics Centre Team on Development of MALDI-MS Assays | GenomeWeb

NEW YORK (GenomeWeb News) – Bruker and the University of Victoria-Genome British Columbia Proteomics Centre said today that they are collaborating on developing high-throughput iMALDI mass spectrometry-based assays for determining genetic hemoglobin variants and diabetes risk.

The assays, which combine peptide immunoenrichment with mass spectrometry for improved throughput and sensitivity, will be developed to run on Bruker's MALDI Biotyper clinical mass spectrometry platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.